Estrogen Receptor α (ERα) and progesterone receptor (PR) expression in male breast cancer is present in around 90% of patients [4], which makes them eligible for adjuvant therapy using tamoxifen and aromatase inhibitors. This evidence concerns the gene PGR and breast cancer.